The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Investigating second-line therapeutic options in hepatocellular carcinoma
Mara Persano, MD, University Hospital of Cagliari, Cagliari, Italy, discusses a retrospective study investigating lenvatinib versus sorafenib as a second-line therapy in patients with hepatocellular carcinoma (HCC) who progressed on atezolizumab plus bevacizumab. Multivariate analysis revealed lenvatinib to be superior than sorafenib, with better overall survival (OS) rates. There is no difference in progression-free survival (PFS) and objective response rate in patients treated with lenvatinib or sorafenib after first line therapy. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
